Skip to main content
An official website of the United States government
Email

Research Activities

Collaborative Tasks

A researcher in a lab coat and goggles working on a laptop in a lab.

The National Cancer Institute’s Office of Cancer Clinical Proteomics Research (OCCPR) is actively involved in several collaborative tasks aimed at advancing cancer research and treatment. These include:

  • CD2 Interagency Task Force: This task force brings together multiple agencies to coordinate cancer diagnostic efforts in cancer research, ensuring a unified approach to tackling cancer-related challenges.
  • EU-U.S. Cancer Health Cooperation Working Group: This working group fosters international collaboration between the European Union and the United States, focusing on shared goals and initiatives in cancer health.

Extramural Research

OCCPR also supports a variety of extramural research programs, which involve partnerships with external organizations and institutions. These programs include:

  • CPTAC: Aims to improve our understanding of cancer biology through the application of proteogenomic technologies.
  • ICPC: Facilitates global collaboration in cancer proteogenomics to accelerate discoveries and improve patient outcomes.
  • APOLLO: Integrates proteogenomics into clinical practice to enhance precision oncology.
  • Antibody Characterization Program: Generates and characterizes affinity reagents for cancer research, ensuring data and protocols are publicly accessible through Antibody Portal.
  • Proteomic Assays: Disseminate highly characterized proteomic assays to the global research community.
  • Kids First: Collaborates with CPTAC to generate and integrate proteomics data with genomics from a subset of current Kids First XO1 childhood cancer cohorts. They aim to enhance the understanding of these cancers and to move toward developing new or improving existing therapeutics for these deadly conditions.
  • CCDI: Collaborates with CPTAC to generate and integrate proteomics data with genomics from subset of these patient samples. Thus, additional layers of omics data are added to provide a more comprehensive picture of the molecular underpinning of pediatric cancer diseases to improve therapeutic outcome.

Science Educational Videos and Podcast

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Research Activities was originally published by the National Cancer Institute.”

Email